Barclays
BCAB icon

Barclays’s BioAtla BCAB Stock Holding History

Barclays’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4
Closed -$126 – 5251
2025
Q3 		$126 Buy
+4
New +$92 ﹤0.01% 5263
2025
Q2 		– Hold
0
– -$2 – 5261
2025
Q1 		– Hold
0
– – – 5210
2024
Q3 		– Sell
-11
Closed -$775 – 5293
2024
Q2 		$775 Sell
11
-613
-98% -$72.9K ﹤0.01% 4696
2024
Q1 		$107K Sell
624
-594
-49% -$73.8K ﹤0.01% 4407
2023
Q4 		$150K Buy
1,218
+1,059
+666% +$91.8K ﹤0.01% 4529
2023
Q3 		$13.5K Sell
159
-18
-10% -$2.29K ﹤0.01% 4252
2023
Q2 		$26.5K Buy
+177
New +$30.4K ﹤0.01% 4076
2023
Q1 		– Sell
-747
Closed -$308K – 5091
2022
Q4 		$308K Buy
747
+709
+1,866% +$294K ﹤0.01% 3611
2022
Q3 		$14K Buy
38
+10
+36% +$3.27K ﹤0.01% 4179
2022
Q2 		$4K Sell
28
-1,306
-98% -$208K ﹤0.01% 4809
2022
Q1 		$333K Buy
+1,334
New +$558K ﹤0.01% 3144

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Barclays's BCAB Position: Q4 2025 in Review

Barclays sold out of BioAtla (BCAB) in Q4 2025, closing a stake of 4 shares — an estimated $126 sold.

Barclays first reported a position in BCAB in Q1 2022 and held it in 10 quarters. The position peaked at $333K in Q1 2022. 41 funds tracked by Wall St. Rank hold BCAB as of Q4 2025.

  • Barclays reported no remaining BioAtla position as of Q4 2025 after selling out during the quarter.
  • Barclays sold 4 BioAtla shares in Q4 2025, an estimated $126.
  • Barclays first reported a position in BioAtla in Q1 2022 and held it in 10 quarters.
  • Barclays's BioAtla position peaked at $333K in Q1 2022.
  • 41 funds tracked by Wall St. Rank held BioAtla as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.